David Gryska
Director/Board Member presso FORTE BIOSCIENCES, INC.
Patrimonio netto: 233 565 $ in data 31/03/2024
Profilo
David W.
Gryska is currently a Director at Mind Medicine (MindMed), Inc. and an Independent Director at Forte Biosciences, Inc. He previously held positions as President, CEO, COO & Director at Myrexis, Inc., Independent Director at Seagen Inc., Director at Phenomix Corp.
and CoTherix, Inc., Independent Director at Aerie Pharmaceuticals, Inc., Lead Independent Director at Hyperion Therapeutics, Inc., Director at GW Pharmaceuticals Ltd., Independent Director at Argos Therapeutics, Inc., and Independent Director at PDL BioPharma, Inc. He also served as Chief Financial Officer & Senior Vice President at Celgene Corp., Chief Financial Officer & Executive Vice President at Incyte Corp., Chief Financial Officer & Senior Vice President at Scios, Inc., and Chief Financial Officer & Vice President-Finance at Cardiac Pathways Corp.
He was also an Audit Partner at Ernst & Young LLP and a Principal at Strategic Consulting Group, Inc. Gryska holds an MBA from Golden Gate University and an undergraduate degree from Loyola University of Chicago.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
21/06/2023 | 13 851 ( 0.02% ) | 130 199 $ | 31/03/2024 | |
FORTE BIOSCIENCES INC.
0.41% | 19/09/2023 | 148 514 ( 0.41% ) | 103 366 $ | 31/03/2024 |
Posizioni attive di David Gryska
Società | Posizione | Inizio |
---|---|---|
FORTE BIOSCIENCES, INC. | Director/Board Member | 10/01/2023 |
MIND MEDICINE (MINDMED) INC. | Director/Board Member | 21/06/2023 |
Precedenti posizioni note di David Gryska
Società | Posizione | Fine |
---|---|---|
SEAGEN INC. | Director/Board Member | 14/12/2023 |
AERIE PHARMACEUTICALS, INC. | Director/Board Member | 21/11/2022 |
GW PHARMACEUTICALS PLC | Director/Board Member | 05/05/2021 |
PDL BIOPHARMA, INC. | Director/Board Member | 31/12/2020 |
INCYTE CORPORATION | Director of Finance/CFO | 31/12/2018 |
Formazione di David Gryska
Loyola University of Chicago | Undergraduate Degree |
Golden Gate University | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
INCYTE CORPORATION | Health Technology |
MYREXIS, INC. | Finance |
MIND MEDICINE (MINDMED) INC. | Health Technology |
Aziende private | 14 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Scios, Inc.
Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
Cardiac Pathways Corp.
Cardiac Pathways Corp. Medical SpecialtiesHealth Technology Cardiac Pathways Corp. designs, develops and manufactures cardiac diagnosis systems. Its products consist principally of systems for performing ablation treatment and for diagnostic mapping. Cardiac Pathways is located in Sunnyvale, CA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
CoTherix, Inc.
CoTherix, Inc. Pharmaceuticals: MajorHealth Technology CoTherix, Inc. develops therapeutic products. Its ventavis product is a nebulizer delivered therapy for pulmonary artery hypertension, which restricts blood flow to the lungs. CoTherix markets its products in the US, Europe, and Australia. The company was founded in February, 2000 by Donald J. Santel and Gerard Turino and is located in Brisbane, CA. | Health Technology |
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Phenomix Corp.
Phenomix Corp. Pharmaceuticals: MajorHealth Technology Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force. | Health Technology |
Hyperion Therapeutics, Inc.
Hyperion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Hyperion Therapeutics, Inc. developed and commercialized pharmaceutical products. The company was founded by Mark Blumling and Christopher Eugene Rivera on November 1, 2006 and headquartered in Brisbane, CA. | Health Technology |
Argos Therapeutics, Inc.
Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Argos Therapeutics, Inc. was a biopharmaceutical company. It engages in development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its proprietary technology platform called Arcelis. The firm's product include AGS-003 for the treatment of metastatic renal cell carcinoma, and other cancers; and AGS-004 for the treatment of human immunodeficiency virus. The company was founded by Bruce A. Sullenger, Eli Gilboa, John A. Irick and Ralph M. Steinman on May 8, 1997 and was headquartered in Durham, NC. | Health Technology |
Medpace, Inc.
Medpace, Inc. Miscellaneous Commercial ServicesCommercial Services Medpace, Inc. provides clinical research services to the pharmaceutical, biotech and medical industries. It offers clinical operations, medical writing, biometrics, regulatory affairs, quality assurance, imaging core lab medical device and risk based monitoring services. The company was founded by August James Troendle in July 1992 and is headquartered in Cincinnati, OH. | Commercial Services |
PDL BioPharma, Inc.
PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
GW Pharmaceuticals Ltd.
GW Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology GW Pharmaceuticals Ltd. operates as an intermediate holding company and management company for investments in its subsidiaries. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Forte Biosciences, Inc. |
- Borsa valori
- Insiders
- David Gryska